← Leaderboards
Richard A Padgett
Cleveland Clinic Foundation
$10,619,978
Attributed
$15,150,333
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$15,150,333 · 11
By mechanism
R01$14,540,577 · 9
R21$609,756 · 2
Top collaborators
- Jaroslaw P Maciejewski13 shared
- Eckhard Jankowsky4 shared
- David Eric Symer4 shared
- Maura L Gillison1 shared
Others in their field
Top investigators on “Rna Splicing”
- Rolf Apweiler · European Molecular Biology Laboratory$41,336,566
- Daniel H Geschwind · University Of California Los Angeles$31,650,067
- Stacey Gabriel · Massachusetts Institute Of Technology$30,450,662
- Brenton R Graveley · University Of Connecticut Sch Of Med/Dnt$30,235,936
- Adrian R Krainer · Cold Spring Harbor Laboratory$28,755,040
- George M Church · Harvard University (Medical School)$26,862,961
Research focus
Rna SplicingSpliceosomesCellsGenesIntronsGene ExpressionMutantMutationIn VivoBaseMolecularPatternAffectMrna PrecursorCell LineDefectAllelesIn VitroSmall Nuclear RnaTranscriptome SequencingGenomicsAlternative SplicingLinkPathogenesis
Grant awards (44)
Functional consequences of mutations in spliceosomal small nuclear RNAs$472,491
R01 · FY2022 · GM · contact PI
Functional consequences of mutations in spliceosomal small nuclear RNAs$471,003
R01 · FY2021 · GM · contact PI
Functional consequences of mutations in spliceosomal small nuclear RNAs$25,145
R01 · FY2021 · GM · contact PI
Functional consequences of mutations in spliceosomal small nuclear RNAs$469,542
R01 · FY2020 · GM · contact PI
Novel Spliceosomal Defects in Myelodysplastic Syndromes$608,289
R01 · FY2019 · HL
Functional consequences of mutations in spliceosomal small nuclear RNAs$481,911
R01 · FY2019 · GM · contact PI
Novel Spliceosomal Defects in Myelodysplastic Syndromes$608,289
R01 · FY2018 · HL
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target$514,645
R01 · FY2018 · HL
Novel Spliceosomal Defects in Myelodysplastic Syndromes$608,289
R01 · FY2017 · HL
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target$514,645
R01 · FY2017 · HL
Investigations of Consequences of U2AF1 Mutations in MDS$396,250
R01 · FY2017 · HL
Novel Spliceosomal Defects in Myelodysplastic Syndromes$622,914
R01 · FY2016 · HL
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target$514,645
R01 · FY2016 · HL
Investigations of Consequences of U2AF1 Mutations in MDS$396,250
R01 · FY2016 · HL
Mechanistic consequences of mutations in spliceosomal snRNAs$380,856
R01 · FY2016 · GM · contact PI
RNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic Target$514,645
R01 · FY2015 · HL
Investigations of Consequences of U2AF1 Mutations in MDS$390,306
R01 · FY2015 · HL
Mechanistic consequences of mutations in spliceosomal snRNAs$380,856
R01 · FY2015 · GM · contact PI
Investigations of Consequences of U2AF1 Mutations in MDS$388,325
R01 · FY2014 · HL
Mechanistic consequences of mutations in spliceosomal snRNAs$382,647
R01 · FY2014 · GM · contact PI
Mechanistic consequences of mutations in spliceosomal snRNAs$398,113
R01 · FY2013 · GM · contact PI
Investigations of Consequences of U2AF1 Mutations in MDS$376,933
R01 · FY2013 · HL
Transcriptional elongation and splicing in human genes in situ$284,981
R01 · FY2013 · GM · contact PI
Transcriptional elongation and splicing in human genes in situ$295,317
R01 · FY2012 · GM · contact PI
Transcriptional elongation and splicing in human genes in situ$295,317
R01 · FY2011 · GM · contact PI
Transcriptional elongation and splicing in human genes in situ$298,300
R01 · FY2010 · GM · contact PI
Mechanism of U12-dependent spliceosomal splicing$290,615
R01 · FY2010 · GM · contact PI
Mechanism of U12-dependent spliceosomal splicing$293,550
R01 · FY2009 · GM · contact PI
Mechanism of U12-dependent spliceosomal splicing$293,550
R01 · FY2008 · GM · contact PI
SCREEN FOR SMALL MOLECULAR INHIBITORS OF MAMMALIAN SPLICEOSOMES$38,625
R21 · FY2008 · NS · contact PI
Mechanism of U12-dependent spliceosomal splicing$293,550
R01 · FY2007 · GM · contact PI
SCREEN FOR SMALL MOLECULAR INHIBITORS OF MAMMALIAN SPLICEOSOMES$193,125
R21 · FY2006 · NS · contact PI
Transcription and processing of very large genes$186,756
R21 · FY2006 · GM · contact PI
Transcription and processing of very large genes$191,250
R21 · FY2005 · GM
SPLICING OF A RARE CLASS OF EUKARYOTIC NUCLEAR INTRONS$260,100
R01 · FY2004 · GM
SPLICING OF A RARE CLASS OF EUKARYOTIC NUCLEAR INTRONS$251,600
R01 · FY2003 · GM
PROTEIN FACTORS IN U12-DEPENDENT PRE-MRNA SPLICING$244,800
R01 · FY2003 · GM
SPLICING OF A RARE CLASS OF EUKARYOTIC NUCLEAR INTRONS$251,600
R01 · FY2002 · GM
PROTEIN FACTORS IN U12-DEPENDENT PRE-MRNA SPLICING$236,800
R01 · FY2002 · GM
SPLICING OF A RARE CLASS OF EUKARYOTIC NUCLEAR INTRONS$251,600
R01 · FY2001 · GM
PROTEIN FACTORS IN U12-DEPENDENT PRE-MRNA SPLICING$236,800
R01 · FY2001 · GM
SPLICING OF A RARE CLASS OF EUKARYOTIC NUCLEAR INTRONS$74,000
R01 · FY2001 · GM
PROTEIN FACTORS IN U12-DEPENDENT PRE-MRNA SPLICING$236,800
R01 · FY2000 · GM
SPLICING OF A RARE CLASS OF EUKARYOTIC NUCLEAR INTRONS$234,308
R01 · FY2000 · GM